Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: A large open-label study in diverse community settings

Annals of Oncology

Volumn 22, Issue 8, 2011, Pages 1812-1823

  Beck, J ^a   Procopio, G ^b   Bajetta, E ^b   Keilholz, U ^c   Negrier, S ^d   Szczylik, C ^e   Bokemeyer, C ^f   Bracarda, S ^g   Richel, D J ^h   Staehler, M ⁱ   Strauss, U P ^j   Mersmann, S ^j   Burock, K ^k   Escudier, B ^l  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d CENTRE LÉON BÉRARD   (France)

^e CENTRAL CLINICAL HOSPITAL   (Poland)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g IRCCS POLICLINICO SAN DONATO   (Italy)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

ⁱ UNIVERSITY OF MUNICH   (Germany)

^j BAYER AG   (Germany)

^k BAYER PHARMA AG   (Germany)

^l INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

Expanded access trials; Protein kinase inhibitors; Renal cell carcinoma; Sorafenib; Tolerability

Indexed keywords

CYTOKINE; SORAFENIB;

ADULT; ADVANCED CANCER; AGE; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COMPASSIONATE USE; CONSTIPATION; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; EUROPE; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEPHRECTOMY; ONCOLOGICAL PARAMETERS; OPEN STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SIDE EFFECT; STOMATITIS; WEIGHT REDUCTION;

EID: 79957802759     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq651     Document Type: Article

References (14)

1. Nexavar [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals, Inc. 2005.
2. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2): 125-134.
3. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27(20): 3312-3318.
4. Bellmunt J, Guix M. The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU Int 2009; 103(5): 572-577.
5. Staehler M, Haseke N, Stadler T et al. Renal surgery in the elderly: morbidity in patients aged >75 years in a contemporary series. BJU Int 2008; 102(6): 684-687.
6. Bellmunt J, Negrier S, Escudier B et al. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG taskforce. Crit Rev Oncol Hematol 2009; 69: 64-72.
7. Eisen T, Oudard S, Szczylik C et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 2008; 100(20): 1454-1463.
8. Stadler W, Figlin R, McDermott D et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib (ARCCS) expanded access program in North America. Cancer 2010; 116(5): 1272-1280.
9. Peters NAJB, Richel DJ, Verhoeff JJC, Stalpers LJA. Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol 2009; 26(14): 2405-2406.
10. Mekhail TM, Abou-Jawde RM, BouMerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23(4): 832-841.
11. Heng DYC, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27(34): 5794-5799.
12. Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded access trial. Lancet Oncol 2009; 10: 757-763.
13. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999; 353: 1695-1700.
14. Shuch B, La Rochelle JC, Wu J et al. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer 2008; 113(6): 1324-1331.